What is B. Riley's Forecast for MDGL Q3 Earnings?

Key Points

• B. Riley forecasts Madrigal Pharmaceuticals to report a Q3 2025 earnings per share of ($0.66), with a buy rating and a price target of $560.00.
• Madrigal Pharmaceuticals reported a revenue of $212.80 million for Q2, significantly exceeding analyst estimates of $158.94 million, showcasing a 1357.5% increase compared to the previous year.
• Analysts have given Madrigal a consensus rating of "Moderate Buy", with price targets ranging from $500.00 to $554.00.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Investment analysts at B. Riley issued their Q3 2025 earnings per share estimates for Madrigal Pharmaceuticals in a research note issued on Monday, September 29th. B. Riley analyst W. Wood anticipates that the biopharmaceutical company will earn ($0.66) per share for the quarter. B. Riley has a "Buy" rating and a $560.00 price target on the stock. The consensus estimate for Madrigal Pharmaceuticals' current full-year earnings is ($23.47) per share. B. Riley also issued estimates for Madrigal Pharmaceuticals' Q4 2025 earnings at $0.83 EPS, FY2025 earnings at ($4.91) EPS, FY2026 earnings at $24.45 EPS, FY2027 earnings at $35.86 EPS and FY2028 earnings at $63.27 EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) EPS for the quarter, beating the consensus estimate of ($3.48) by $1.58. The firm had revenue of $212.80 million during the quarter, compared to analyst estimates of $158.94 million. Madrigal Pharmaceuticals had a negative return on equity of 38.38% and a negative net margin of 54.68%.The business's quarterly revenue was up 1357.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($7.10) earnings per share.

Several other equities research analysts have also commented on the company. TD Cowen upped their price target on Madrigal Pharmaceuticals from $390.00 to $554.00 and gave the stock a "buy" rating in a research note on Tuesday, August 26th. Canaccord Genuity Group upped their price target on Madrigal Pharmaceuticals from $428.00 to $526.00 and gave the stock a "buy" rating in a research note on Friday, September 12th. UBS Group restated a "buy" rating and set a $523.00 price target (up from $458.00) on shares of Madrigal Pharmaceuticals in a research note on Tuesday, August 12th. Cowen restated a "buy" rating on shares of Madrigal Pharmaceuticals in a research note on Tuesday, August 26th. Finally, HC Wainwright assumed coverage on Madrigal Pharmaceuticals in a research note on Thursday, September 4th. They set a "buy" rating and a $500.00 price target for the company. Nine analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $495.88.

Madrigal Pharmaceuticals Stock Performance

Shares of NASDAQ:MDGL opened at $449.14 on Thursday. The firm has a market capitalization of $9.97 billion, a PE ratio of -34.95 and a beta of -1.02. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.11 and a quick ratio of 4.78. The business has a 50-day moving average of $394.79 and a two-hundred day moving average of $336.02. Madrigal Pharmaceuticals has a 12 month low of $200.63 and a 12 month high of $463.63.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of MDGL. VSM Wealth Advisory LLC purchased a new position in Madrigal Pharmaceuticals in the first quarter valued at about $25,000. Accent Capital Management LLC acquired a new stake in Madrigal Pharmaceuticals during the first quarter valued at approximately $25,000. AlphaQuest LLC raised its stake in Madrigal Pharmaceuticals by 412.5% during the second quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 66 shares in the last quarter. Summit Securities Group LLC acquired a new stake in Madrigal Pharmaceuticals during the first quarter valued at approximately $33,000. Finally, Farther Finance Advisors LLC raised its stake in Madrigal Pharmaceuticals by 825.0% during the first quarter. Farther Finance Advisors LLC now owns 111 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 99 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company's stock.

Insider Transactions at Madrigal Pharmaceuticals

In related news, CEO William John Sibold sold 7,616 shares of the stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $400.18, for a total value of $3,047,770.88. Following the completion of the transaction, the chief executive officer owned 109,753 shares of the company's stock, valued at approximately $43,920,955.54. This represents a 6.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Kenneth Bate sold 10,000 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $365.20, for a total value of $3,652,000.00. Following the completion of the transaction, the director directly owned 2,627 shares of the company's stock, valued at $959,380.40. This represents a 79.20% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have bought 165,683 shares of company stock valued at $61,921,142 and have sold 309,019 shares valued at $112,705,072. Company insiders own 21.50% of the company's stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.